Adrecizumab is a humanized murine monoclonal IgG1 antibody specifically binding the N-terminal region of human Adrenomedullin. It will be a first-in-class drug that targets and balances an essential reagulator of vascular activity.
- High Preclinical Efficacy: In several resuscitated vascular integrity models (mouse, rat, pig), Adrecizumab has shown to improve all clinically relevant end points. It reduces vascular leakage, stabilizes the circulation, by restoring blood pressure, normalizing fluid balance and reducing vasopressor demand, improves renal function and reduces mortality from septic shock by 50% (For further details see below or our publication list).
- GMP Material available: A genereic Good Manufacturing Practice (GMP) process is established and sufficient GMP material for Clinical Phases I and II is available.
- Strong Patent Position: Adrenomed AG owns six patent families, two already issued in an EP and US patent, that effectively secures our business.
- Excellent Safety: Regulatory (GLP) Toxicology & Safety studies in healthy rodents (rats) and non-rodents (dogs and non-human primates) showed that Adrecizumab is well tolerated and has an excellent safety profile.
- Phase I: Safety & Tolerability in healthy subjects confirmed
- Phase II Goal: Demonstrate Safety & Tolerability, Dose Finding & Effect Size Estimation for Phase III
Adrecizumab has shown to improve all clinically relevant end points in several resuscitated animal models of vascular integrity (mouse, rat, pig). It reduces vascular leakage, stabilizes the circulation, by restoring blood pressure and reducing vasopressor demand, improves renal function and reduces mortality from septic shock by 50%.
Adrecizumab restores blood pressure
Blood pressure [in mmHg] of healthy rats (Healthy) and of rats after sepsis induction (CLP model), either treated with Adrecizumab or an unspecific control antibody (control). Adapted from Blet et al. Intensive Care Med Exp 2015, 3(Suppl 1):A618.
Adrecizumab reduces mortality by 50%
Survival rate of rats after sepsis induction (CLP model), either treated with Adrecizumab or an unspecific control antibody. Adapted from Struck et al. Intensive Care Medicine Experimental 2013, 1:3.